M. Budde

1.9k total citations
27 papers, 1.4k citations indexed

About

M. Budde is a scholar working on Oncology, Statistics and Probability and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, M. Budde has authored 27 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Statistics and Probability and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in M. Budde's work include Bone health and treatments (7 papers), Statistical Methods in Clinical Trials (7 papers) and Acute Myeloid Leukemia Research (6 papers). M. Budde is often cited by papers focused on Bone health and treatments (7 papers), Statistical Methods in Clinical Trials (7 papers) and Acute Myeloid Leukemia Research (6 papers). M. Budde collaborates with scholars based in Switzerland, Germany and United States. M. Budde's co-authors include Vincent Charlon, Henry Krum, Reuven J. Viskoper, Yves Lacourcière, B. Bergström, М. Р. Личиницер, Jean‐Jacques Body, Ingo Diel, E.D. Kreuser and W. Dornoff and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of the American Statistical Association.

In The Last Decade

M. Budde

27 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Budde Switzerland 12 633 321 305 241 238 27 1.4k
Marina Κita Greece 28 257 0.4× 178 0.6× 163 0.5× 88 0.4× 72 0.3× 78 2.2k
Yoshiaki Kawaguchi Japan 22 458 0.7× 548 1.7× 282 0.9× 571 2.4× 64 0.3× 102 2.2k
Erdal Çavuşoğlu United States 23 365 0.6× 814 2.5× 193 0.6× 253 1.0× 117 0.5× 68 1.9k
MA Goldberg United States 14 204 0.3× 193 0.6× 238 0.8× 155 0.6× 81 0.3× 24 1.6k
Solveig Wållberg‐Jonsson Sweden 24 136 0.2× 586 1.8× 122 0.4× 208 0.9× 125 0.5× 50 2.5k
Hilary A. Capell United Kingdom 10 155 0.2× 278 0.9× 94 0.3× 139 0.6× 130 0.5× 22 2.6k
Ki‐Hyun Baek South Korea 22 294 0.5× 139 0.4× 179 0.6× 75 0.3× 141 0.6× 116 1.6k
Masayuki Yamanouchi Japan 23 167 0.3× 116 0.4× 127 0.4× 405 1.7× 79 0.3× 195 2.1k
Patrick H Dessein South Africa 26 141 0.2× 544 1.7× 159 0.5× 115 0.5× 103 0.4× 86 2.7k
Tímea Gombos Hungary 15 482 0.8× 209 0.7× 72 0.2× 165 0.7× 54 0.2× 21 1.0k

Countries citing papers authored by M. Budde

Since Specialization
Citations

This map shows the geographic impact of M. Budde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Budde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Budde more than expected).

Fields of papers citing papers by M. Budde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Budde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Budde. The network helps show where M. Budde may publish in the future.

Co-authorship network of co-authors of M. Budde

This figure shows the co-authorship network connecting the top 25 collaborators of M. Budde. A scholar is included among the top collaborators of M. Budde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Budde. M. Budde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Body, J.J., M. Lichinitser, S. Tjulandin, M. Budde, & B. Bergström. (2005). Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: Results from a comparative phase III trial. Journal of Clinical Oncology. 23(16_suppl). 534–534. 11 indexed citations
2.
Robson, Richard A., J. Michael Cecka, Gerhard Opelz, M. Budde, & Susan T. Sacks. (2005). Prospective Registry‐Based Observational Cohort Study of the Long‐Term Risk of Malignancies in Renal Transplant Patients Treated with Mycophenolate Mofetil. American Journal of Transplantation. 5(12). 2954–2960. 179 indexed citations
3.
Budde, M., et al.. (2004). Biochemical bone turnover markers are useful tools to assess changes in bone metabolism in marmosets. Journal of Bone and Mineral Metabolism. 22(3). 192–197. 5 indexed citations
4.
Diel, Ingo, Jean‐Jacques Body, М. Р. Личиницер, et al.. (2004). Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer. 40(11). 1704–1712. 112 indexed citations
5.
Moecks, Joachim, et al.. (2004). Measures of Morbidity in Clinical Studies with Recurrent Skeletal Complications. Journal of Biopharmaceutical Statistics. 14(2). 415–437. 3 indexed citations
6.
Tripathy, Debu, A. F Lazarev, Sharon MacLachlan, et al.. (2004). Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Annals of Oncology. 15(5). 743–750. 68 indexed citations
7.
Body, Jean‐Jacques, et al.. (2004). Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: Results of an open-label study. Journal of Clinical Oncology. 22(14_suppl). 735–735. 5 indexed citations
8.
Body, Jean‐Jacques, Ingo Diel, М. Р. Личиницер, et al.. (2003). Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology. 14(9). 1399–1405. 296 indexed citations
9.
Scott, Martin, et al.. (2003). Morbidity measures in the presence of recurrent composite endpoints. Pharmaceutical Statistics. 2(1). 39–49. 7 indexed citations
10.
Bruijn, Sebastiaan F.T.M. de, et al.. (2000). Long-term outcome of cognition and functional health after cerebral venous sinus thrombosis. Neurology. 54(8). 1687–1689. 73 indexed citations
11.
Krum, Henry, Reuven J. Viskoper, Yves Lacourcière, M. Budde, & Vincent Charlon. (1998). The Effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential Hypertension. New England Journal of Medicine. 338(12). 784–791. 449 indexed citations
12.
Bauer, Péter & M. Budde. (1994). Multiple Testing for Detecting Efficient Dose Steps. Biometrical Journal. 36(1). 1–15. 10 indexed citations
13.
Maw, R D, W W Dinsmore, Tara Homer, et al.. (1991). A comparison of interferon alfa-2a and podophyllin in the treatment of primary condylomata acuminata. The Condylomata International Collaborative Study Group.. Sexually Transmitted Infections. 67(5). 394–399. 3 indexed citations
14.
Budde, M. & Péter Bauer. (1989). Multiple Test Procedures in Clinical Dose Finding Studies. Journal of the American Statistical Association. 84(407). 792–796. 30 indexed citations
15.
16.
Creutzig, Ursula, J. Ritter, H. Riehm, M. Budde, & G. Schellong. (1987). The Childhood AML Studies BFM-78 and -83: Treatment Results and Risk Factor Analysis. Hämatologie und Bluttransfusion. 30. 71–75. 13 indexed citations
17.
Creutzig, Ursula, J. Ritter, M. Budde, et al.. (1987). Treatment Results in Childhood AML, with Special Reference to the German Studies BFM-78 and BFM-83. Hämatologie und Bluttransfusion. 31. 30–34. 1 indexed citations
18.
Ludwig, W.-D., F. Herrmann, M. Budde, et al.. (1987). Surface Marker Analysis by Monoclonal Antibodies: A Valuable Technique in Childhood Acute Myeloid Leukemia. Hämatologie und Bluttransfusion. 30. 418–422. 1 indexed citations
19.
Hiddemann, W., Jochen Harbott, H. Haas, et al.. (1987). Nachweis von Aberrationen des Karyotyps bei Kindern mit akuten Leukämien: eine vergleichende Analyse von Zytogenetik und Durchflußzytophotometrie. Klinische Pädiatrie. 199(3). 161–164. 4 indexed citations
20.
Hiddemann, W., J. Ritter, Bernhard Wörmann, et al.. (1985). DNS-Aneuploidie bei Kindern mit akuten Leukämien: I. Inzidenz und klinische Bedeutung im Rahmen der BFM-Studien. Klinische Pädiatrie. 197(3). 215–220. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marina Κita Breakdown of academic impact, for papers by Yoshiaki Kawaguchi Breakdown of academic impact, for papers by Erdal Çavuşoğlu Breakdown of academic impact, for papers by MA Goldberg Breakdown of academic impact, for papers by Solveig Wållberg‐Jonsson Breakdown of academic impact, for papers by Hilary A. Capell Breakdown of academic impact, for papers by Ki‐Hyun Baek Breakdown of academic impact, for papers by Masayuki Yamanouchi Breakdown of academic impact, for papers by Patrick H Dessein Breakdown of academic impact, for papers by Tímea Gombos
Rankless by CCL
2026